Výsledky vyhledávání - "L. von Moltke"

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Investigational Microbiome Therapeutic SER-109 Reduces Recurrence of Clostridioides DifficileInfection (CDI) Compared to Placebo, Regardless of Presence or Absence of Comorbidities Including Chronic Obstructive Disease (COPD) and Asthma

Autor: B.H. McGovern, T. Louie, S. Cohen, M. Sims, E. Wang, H. Wu, K. Brady, L. von Moltke

Publikováno v: B39. COPD MANAGEMENT: FROM PHARMACOLOGIC TREATMENT TO NOVEL THERAPIES.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b43151853ce52e81ef17662b6b334f1c
https://doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a2792

Zobrazit plný text záznamu

Pharmacological profile of ALKS 7119, an investigational compound evaluated for the treatment of neuropsychiatric disorders, in healthy volunteers

Autor: Francis M. Dijkstra, Rob G. J. A. Zuiker, Pieter S. Siebenga, Richard A. Leigh‐Pemberton, Lei Sun, Joan D. Manthis, Marieke L. de Kam, Richard Lin, Lisa L. von Moltke, David Rezendes, Joop M. A. van Gerven

Publikováno v: British journal of clinical pharmacology. 88(6)

ALKS 7119 is a novel compound with in vitro affinity highest for the SERT, and for μ receptor, αIn 10 cohorts (n = 10 subjects each), PK, safety and PD (NeuroCart tests, measuring neurophysiologic effects [pupillometry, pharmaco-EEG (pEEG)], visuom

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54111141f30b8fbea7e0c8b0dfaf0d90
https://pubmed.ncbi.nlm.nih.gov/35014069

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Drug-Drug Interactions: Clinical Perspective

Autor: David J. Greenblatt, Lisa L. von Moltke

Publikováno v: Drug-Drug Interactions ISBN: 9780429131967

During the last 20 years, the general problem of pharmacokinetic drug interactions has received increasing attention. Over this period a number of new and unique classes of medications have been introduced into clinical practice. Principal objective

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::02ed7fcf8820e6e122dad270c6212fa9
https://doi.org/10.1201/9780429131967-15

Zobrazit plný text záznamu

143 A Combination of Olanzapine and Samidorphan Has No Clinically Relevant Effect on QT Prolongation up to Supratherapeutic Doses

Autor: Lisa L. von Moltke, Hongqi Xue, Bhaskar Rege, Borje Darpo, Narinder Nangia, Randy Brown, Lei Sun, Sergey Yagoda, David McDonnell

Publikováno v: CNS Spectrums. 25:291-291

Background:ALKS 3831, a combination of olanzapine and samidorphan (OLZ/SAM) in development for schizophrenia, is intended to mitigate olanzapine-associated weight gain. This thorough QT (tQT) study evaluated OLZ/SAM effects on electrocardiogram param

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::acf01def7c9bbabbeeb6cf54123c168a
https://doi.org/10.1017/s1092852920000590

Zobrazit plný text záznamu

Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia

Autor: David P. Walling, Marjie L. Hard, Angela Wehr, Yangchun Du, Lisa L. von Moltke, Peter J. Weiden

Publikováno v: Journal of clinical psychopharmacology. 38(5)

Background Aripiprazole lauroxil (AL), a long-acting injectable antipsychotic for the treatment of schizophrenia, requires 21 days of oral aripiprazole supplementation upon initiation. We report findings from a phase 1 study investigating a nanocryst

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea6ecc38b59411e7e8d68ef0744880da
https://pubmed.ncbi.nlm.nih.gov/30015676

Zobrazit plný text záznamu

P.755 ALKS 3831, a combination of olanzapine and samidorphan, has no clinically relevant effect on QT prolongation up to supratherapeutic doses

Autor: B. Darpo, L. Sun, S. Yagoda, H. Xue, R. Brown, N. Nangia, D. McDonnell, B. Rege, L. Von Moltke

Publikováno v: European Neuropsychopharmacology. 29:S507-S508

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c20406f2561a4e63e05509934ff32ffc
https://doi.org/10.1016/j.euroneuro.2019.09.790

Zobrazit plný text záznamu

27 A New Method for Initiating Treatment with the Long-acting Antipsychotic Aripiprazole Lauroxil

Autor: Rakesh Jain, Jonathan M. Meyer, Bhaskar Rege, Peter J. Weiden, Angela Wehr, Lisa L. von Moltke

Publikováno v: CNS Spectrums. 24:188-189

STUDY OBJECTIVESlow release is a fundamental feature of long-acting injectable (LAI) antipsychotics. This property allows continuous drug exposure between dosing intervals. However, there can be a significant delay between giving the first LAI dose a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c0007bf41ce63544582384e5e07bc5b2
https://doi.org/10.1017/s109285291900021x

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání